Traders Sell Shares of Regeneron Pharmaceuticals (REGN) on Strength (REGN)

Investors sold shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on strength during trading on Friday. $64.14 million flowed into the stock on the tick-up and $85.45 million flowed out of the stock on the tick-down, for a money net flow of $21.31 million out of the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $2.66 for the day and closed at $381.17

A number of brokerages have recently issued reports on REGN. BidaskClub raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 1st. Argus reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 13th. Oppenheimer set a $440.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, December 2nd. Leerink Swann set a $483.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 7th. They noted that the move was a valuation call. Finally, TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Tuesday, November 13th. One investment analyst has rated the stock with a sell rating, seventeen have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $406.89.

The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. The stock has a market capitalization of $41.25 billion, a price-to-earnings ratio of 28.42, a price-to-earnings-growth ratio of 1.68 and a beta of 1.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The firm had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same quarter in the prior year, the business earned $3.99 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals Inc will post 18.88 earnings per share for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $388.65, for a total transaction of $777,300.00. Following the completion of the transaction, the director now owns 13,000 shares in the company, valued at $5,052,450. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 4,006 shares of company stock valued at $1,564,114. 12.42% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc lifted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. Rehmann Capital Advisory Group lifted its position in Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 68 shares during the last quarter. Vanguard Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. Morgan Stanley lifted its position in Regeneron Pharmaceuticals by 70.6% during the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock valued at $187,719,000 after purchasing an additional 192,236 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in Regeneron Pharmaceuticals by 2.5% during the third quarter. Legal & General Group Plc now owns 360,002 shares of the biopharmaceutical company’s stock valued at $145,455,000 after purchasing an additional 8,792 shares during the last quarter. Institutional investors and hedge funds own 67.24% of the company’s stock.

WARNING: This story was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/12/16/traders-sell-shares-of-regeneron-pharmaceuticals-regn-on-strength-regn.html.

Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Does the discount rate affect the economy?

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply